Related Experiment Video
Updated: Jul 13, 2026

Pluripotent Stem Cell Derived Cardiac Cells for Myocardial Repair
Published on: February 3, 2017
G-CSF-based stem cell therapy for the heart-unresolved issues part A: paracrine actions, mobilization, and delivery
1Department of Chemistry and Life Sciences, College of Sciences and Engineering, Holy Spirit University of Kaslik, Jounieh, Lebanon.
Insights
Granulocyte colony-stimulating factor (G-CSF) therapy shows promise for heart repair despite past trial failures. Recent science explains setbacks and guides future G-CSF applications for cardiac recovery.
Area of Science:
- Cardiovascular Research
- Regenerative Medicine
- Stem Cell Biology
Background:
- Large clinical trials using G-CSF for myocardial infarction showed disappointing results.
- Previous animal and small human studies suggested G-CSF's potential for cardiac repair.
- Recent scientific advances offer new insights into G-CSF's mechanisms and therapeutic potential.
Purpose of the Study:
- To explain the failure of previous large-scale G-CSF clinical trials.
- To review recent advances in G-CSF's direct protective effects on cardiac cells.
- To explore G-CSF's role in stem cell mobilization and cardiac delivery for heart repair.
Main Methods:
- Review of recent basic science findings.
- Analysis of G-CSF's direct actions on cardiomyocytes.
- Examination of stem cell mobilization and homing mechanisms.
- Evaluation of G-CSF-related therapies for injured hearts.
Main Results:
- G-CSF has direct protective effects on cardiac cells.
- Understanding G-CSF's mechanisms can explain prior clinical trial failures.
- New strategies for G-CSF-based stem cell therapy are emerging.
- Advances in stem cell mobilization and delivery are promising.
Conclusions:
- G-CSF-based therapies for cardiac repair warrant further investigation.
- Recent scientific discoveries provide a rationale for revitalizing G-CSF research.
- Optimized G-CSF strategies could lead to effective clinical applications for heart disease.
Abstract:
The results of large-scale clinical trials involving granulocyte colony-stimulating factor (G-CSF)-based mobilization of bone marrow stem cells to improve cardiac remodeling and function after acute myocardial infarction have been disappointing. These trials came about as the result of an explosion of animal studies reporting dramatic successes with this therapeutic approach and small-scale nonrandomized, nonblinded clinical trials suggesting beneficial effects in humans as well. It would be rash to conclude, however, that G-CSF-based stem cell therapies for repairing the injured or failing heart are not worth pursuing. Recent advances in basic science not only help explain the failure of the larger clinical trials but have revitalized interest into using G-CSF-based or G-CSF-related therapies for the injured heart. This article will provide an overview of recent advances that have been made in the direct protective actions of G-CSF on cardiac cells, the mobilization of stem cells from the bone marrow, and the delivery of these cells to the heart. Such knowledge could be readily exploited to make G-CSF-based therapy a reality for the clinician.
Related Concept Videos
Regulation of Hematopoietic Stem Cells
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Stem Cell Culture
Mesenchymal Stem Cells

